Molbio Diagnostics Jumps 15% — The Numbers Behind the Rally

Spread love

By S. JHA

Six weeks after listing, this diagnostics maker has gained as much as 87% over its IPO price. A fresh brokerage note and a large institutional stake purchase both landed in the same 48 hours — but the company’s own reported earnings per share have collapsed, not grown, over the past year.

Mumbai, October 2, 2026 — Shares of Molbio Diagnostics Ltd rose 15.32% on Thursday, touching ₹1,510.00 on the BSE against a previous close of ₹1,309.45, according to data from Rediff Money. The stock traded in a wide intraday range of ₹1,309.45 to ₹1,569.80 on volume of 1.34 million shares, giving the Goa-based diagnostics maker a market capitalization of ₹17,395.21 crore.

The move has a clear, identifiable trigger. Business Upturn and 5paisa both reported that HDFC Mutual Fund purchased a 1.99% stake in Molbio Diagnostics through a bulk deal — with Rediff’s own news feed on the stock specifically headlining it as “Motilal Oswal Sells Molbio Stake for Rs 306 Cr; HDFC Buys.” Business Upturn placed the stock’s intraday high at ₹1,564.30 by midday, with volume exceeding 59 lakh shares — the kind of institutional ownership handoff that often draws further momentum buying once disclosed.

A Rally That Was Already Running Hot Before Today

Today’s gain is, notably, not an isolated spike — it’s the latest leg of a rally that had already accelerated sharply in the prior session. Business Standard reported that Molbio Diagnostics hit its 20% upper circuit at ₹1,509.70 on the BSE on September 30, with the stock up 35% over just two trading days and 87% above its ₹807 IPO issue price, on combined volume of 12.31 million shares and pending unfilled buy orders for a further 370,000 shares. That same day, the stock had gained 9% specifically after Jefferies initiated coverage with a ‘Buy’ rating and a target price of ₹1,600 — calling Molbio a “high-conviction pick” built around continued expansion of its Truenat point-of-care diagnostics platform, scale-up of its Prorad portable X-ray portfolio, and the planned US commercial rollout of its Optrascan digital pathology business.

What’s striking about that sequence is the math it leaves behind: with the stock trading at ₹1,510, it now sits within roughly 6% of Jefferies’ own 12-month target of ₹1,600 — a gap the market has nearly closed within 48 hours of the target being published. When a stock’s price catches up to its most bullish covering analyst’s full-year target in a matter of days, it’s worth asking whether the subsequent move is still being driven by that analyst’s thesis, or by separate, self-reinforcing momentum.

The IPO Context

Molbio listed on the NSE and BSE on August 17, 2026, debuting at ₹980 — a roughly 21% premium over its ₹807 issue price — before closing its first session at ₹1,041.70, about 29% above issue. The stock’s 52-week range, per Rediff’s data, spans ₹925.80 to ₹1,686.50, meaning even Thursday’s rally sits comfortably below the stock’s own all-time intraday high touched earlier in its short trading history.

Here is the detail that deserves the closest scrutiny. Rediff’s data for Molbio shows reported EPS of ₹12.83 for the year ended March 2026 — a steep decline from ₹61.98 in FY25, ₹49.29 in FY24, and ₹83.35 in FY22. That’s not a company whose underlying profitability is collapsing in absolute terms: the same data shows gross profit of ₹236.42 crore in FY26, actually slightly higher than FY25’s ₹223.14 crore, with sales growing a healthy 35% year-on-year to ₹1,313.40 crore. The disconnect between roughly flat absolute profit and a more than 75% collapse in per-share earnings points to one explanation: a substantial increase in the company’s outstanding share count, consistent with dilution from the IPO process itself and any pre-listing bonus or share-split adjustments.

That matters directly for how investors should read the stock’s current valuation. Rediff’s data shows a trailing P/E ratio of 102.09 — an expensive multiple under any circumstance, but one built on a freshly diluted, single-year EPS figure that bears little resemblance to the company’s EPS history just two years earlier. Investors comparing Molbio’s current multiple to its own past “cheapness” are not making a like-for-like comparison, given how dramatically the per-share earnings base has shifted around the listing.

None of this is to say the underlying growth story is fabricated. Geojit Investments’ assessment, cited by Business Standard, noted Molbio delivered revenue, EBITDA, and PAT growth at compound annual rates of 32%, 17%, and 11% respectively over FY24-FY26, driven by rising Truenat platform sales and higher test-kit volumes.

Follow The Raisina Hills on WhatsApp, Instagram, YouTube, Facebook, and LinkedIn